Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Breast cancers that are ER/PR negative and HER-2/neu nonamplified are more likely than those without triple negative status to show a complete pathologic…
NEW YORK (Reuters Health) – The presence of multiple single nucleotide polymorphisms (SNPs) associated with increased prostate cancer risk, coupled with a positive family history, accurately identify men…
NEW YORK (Reuters Health) – High urinary levels of a carcinogen in tobacco may help predict risk of lung cancer in smokers, according to research reported at the…
NEW YORK (Reuters Health) – Overall, women who were treated for cancer during childhood are about 20% less likely to become pregnant than their unaffected sisters, according to…
NEW YORK (Reuters Health) – Stereotactic body radiation therapy (SBRT) for early-stage non-small-cell lung cancer (NSCLC) results in “excellent 3-year local control and survival rates,” researchers report based…
NEW YORK (Reuters Health) – Although folate fortification of foods may reduce the rate of neural tube defects in target populations, new research from Chile suggests that it…
NEW YORK (Reuters Health) – New research suggests that marijuana use may increase the risk of testicular germ cell tumors (TGCTs), primarily nonseminoma types. According to the report…
NEW YORK (Reuters Health) – Women with synchronous primary ovarian and endometrial cancers have better survival rates than women with single ovarian cancers do, according to a report…
NEW YORK (Reuters Health) – Use of a high cut-off dialyzer can help patients with acute renal failure secondary to multiple myeloma become dialysis free, the results of…
NEW YORK (Reuters Health) For patients with epidermal growth factor (EGF) receptor-positive colorectal cancer and unresectable metastases, adding cetuximab to first-line treatment with irinotecan, fluorouracil, and leucovorin (FOLFIRI)…
